{"id":"W4405861407","doi":"10.1016/j.lungcan.2024.108066","title":"FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)","year":2024,"lang":"en","type":"review","venue":"Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Exon; Oncology; Internal medicine; Chemotherapy; Mutation; Cancer research; Gene; Genetics; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008655113,0.0006698259,0.001922649,0.0002819565,0.0001379414,0.00003351109,0.0001082656,0.0002544967,0.0002647304],"category_scores_gemma":[0.00002839411,0.0004271774,0.0008361348,0.0005427267,0.00007341672,0.0001031197,0.00001382311,0.0001847154,0.00001635916],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001800913,"about_ca_system_score_gemma":0.001880283,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003700403,"about_ca_topic_score_gemma":0.00047167,"domain_scores_codex":[0.9976166,0.00004314166,0.0009092269,0.0007166655,0.0003422677,0.0003720947],"domain_scores_gemma":[0.99834,0.0001572209,0.0005901653,0.000518619,0.000210981,0.0001830747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0283881,0.002093132,0.000003342322,0.01550456,0.005370699,0.00003372568,0.0007427498,0.00007079105,0.000007155865,0.00007087733,0.001519824,0.9461951],"study_design_scores_gemma":[0.1072116,0.008747404,0.00000201657,0.01846473,0.02341985,0.00002440719,0.00003366571,0.0001367698,0.00007429755,0.00003549522,0.8414756,0.0003741567],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009969791,0.983407,0.0002879945,0.001097076,0.0009423842,0.01082733,0.001642575,0.0001262135,0.000672416],"genre_scores_gemma":[0.001015442,0.9706665,0.0005464706,0.0001139549,0.0008285551,0.01398135,0.003559215,0.0001986064,0.009089946],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9458209,"threshold_uncertainty_score":0.999818,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04779677523494436,"score_gpt":0.4626471629771375,"score_spread":0.4148503877421932,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}